Xoma | XOMA - Cost Of Sales


Xoma reported 116K in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Agenus USD 642K 399K Sep/2025
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Ardelyx USD 4.81M 6.04M Mar/2026
aTyr Pharma USD 1.31M 2.04M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Celldex Therapeutics USD 54.2M 8.94M Jun/2025
Curis USD 314K 9.96M Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Emergent BioSolutions USD 381.2M 226.1M Jun/2023
Incyte USD 104.5M 16.68M Mar/2026
MacroGenics USD 9.53M 585K Mar/2026
Novartis USD 3.46B 83M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Xoma 116K 112.7K Jun/2024